Opendata, web and dolomites

BabyLux

Launching the First Non-Invasive Brain-Monitoring System for the Early Detection and Management of Encephalopathy In Preterm Babies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BabyLux project word cloud

Explore the words cloud of the BabyLux project. It provides you a very rough idea of what is the project "BabyLux" about.

invasive    nicus    weeks    clinical    entrance    extremely    intensive    maintaining    accurate    damage    million    lasting    solving    babylux    born    monitoring    figures    live    worldwide    business    stage    premature    combining    assumptions    risk    techniques    photonic    preterm    flow    gestational    reaching    leads    fall    unsolved    affordable    device    last    precise    autism    deficit    suffering    period    gain    tremendously    compilation    neonates       market    cerebral    decades    alive    first    20    mixed    markets    hemophotonics    hearing    fact    15    sold    oxygen    paralysis    babies    time    requesting    sub    anyhow    partial    model    segment    200m    units    months    37    carg    failing    commercialization    brain    metabolism    13    despite    detect    visual    disorders    artificial    care    neonatal    gestation    births    blood    easing    commercial    until    credibility    lifelong    segments    encephalopathies    manner    corroborate    community    hospitals    successful    turnover    impairments    smei    solutions    scientific    2014    over   

Project "BabyLux" data sheet

The following table provides information about the project.

Coordinator
HEMOPHOTONICS SL 

Organization address
address: AVENIDA CARL FRIEDRICH GAUSS 3 OFICINA 346 MEDITERRANEAN TECHNOLOGY PARK
city: CASTELLDEFELS
postcode: 8860
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.hemophotonics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOPHOTONICS SL ES (CASTELLDEFELS) coordinator 50˙000.00

Map

 Project objective

Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments. To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques. Our product fall within the sub-segment of “monitoring equipment” for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BABYLUX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BABYLUX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Gestoos (2017)

The first Behavior Recognition Open Platform

Read More  

Demographica (2017)

Helping marketing campaigns go viral

Read More